Tocilizumab for the treatment of rheumatoid arthritis

TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198): review decision - September 2013 information

TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198): Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 226 KB)

TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198): review proposal - July 2013 information

TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198): Appendix A provisional matrix of stakeholders (PDF 42 KB)

TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198): Appendix B proposal paper presented to the Institute's Guidance Executive (PDF 519 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): EIA form guidance development (PDF 75 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): final appraisal determination information

Rheumatoid arthritis - tocilizumab (rapid review TA198): final appraisal determination document (PDF 296 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): response to consultee, commentator and public comments on the Appraisal Consultation Document (PDF 419 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): consultee and commentator comments on the ACD

Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from MSD (PDF 556 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from Roche (PDF 179 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from the British Society of Rheumatology (PDF 114 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from the Royal College of Nursing (PDF 82 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from Abbott (PDF 127 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): comment received from Pfizer (PDF 225 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): appraisal consultation

Rheumatoid arthritis - tocilizumab (rapid review TA198): appraisal consultation document information

www.nice.org.uk/guidance/TA/Wave24/16 information

Rheumatoid arthritis - abatacept (2nd line): EIA form (guidance development) (PDF 23 KB)

Rheumatoid arthritis - abatacept (2nd line): press release information

2011/101 NICE appraisal on abatacept for rheumatoid arthritis (PDF 71 KB)

Rheumatoid arthritis - abatacept (2nd line): final appraisal determination information

Rheumatoid arthritis - abatacept (2nd line): final appraisal determination document (PDF 295 KB)

Rheumatoid arthritis - abatacept (2nd line): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 368 KB)

Rheumatoid arthritis - abatacept (2nd line): consultee and commentator comments on the ACD

Rheumatoid arthritis - abatacept (2nd line): Bristol-Myers Squibb (PDF 593 KB)

Rheumatoid arthritis - abatacept (2nd line): Arthritis Care (PDF 64 KB)

Rheumatoid arthritis - abatacept (2nd line): National Rheumatoid Arthritis Society (PDF 229 KB)

Rheumatoid arthritis - abatacept (2nd line): British Society for Rheumatology (PDF 165 KB)

Rheumatoid arthritis - abatacept (2nd line): Royal College of Nursing (PDF 61 KB)

Rheumatoid arthritis - abatacept (2nd line): Royal College of Pathology (PDF 44 KB)

Rheumatoid arthritis - abatacept (2nd line): Department of Health (PDF 80 KB)

Rheumatoid arthritis - abatacept (2nd line): Commissioning Support Appraisal Service (PDF 436 KB)

Rheumatoid arthritis - abatacept (2nd line): Abbott (PDF 86 KB)

Rheumatoid arthritis - abatacept (2nd line): Merck Sharpe and Dohme (PDF 128 KB)

Rheumatoid arthritis - abatacept (2nd line): Pfizer (PDF 306 KB)

Rheumatoid arthritis - abatacept (2nd line): comments on the ACD received from the public through the NICE website (PDF 59 KB)

Rheumatoid arthritis - abatacept (2nd line): appraisal consultation

Rheumatoid arthritis - abatacept (2nd line): appraisal consultation document information

Rheumatoid arthritis - abatacept (2nd line): evaluation report

Rheumatoid arthritis - abatacept (2nd line): pre-meeting briefing (PDF 156 KB)

Rheumatoid arthritis - abatacept (2nd line): Evidence Review Group report

Rheumatoid arthritis - abatacept (2nd line): Evidence Review Group report (PDF 1.32 MB)

Rheumatoid arthritis - abatacept (2nd line): ERG factual error check (PDF 179 KB)

Rheumatoid arthritis - abatacept (2nd line): non-manufacturer submissions

Rheumatoid arthritis - abatacept (2nd line): British Health Professionals in Rheumatology (PDF 57 KB)

Rheumatoid arthritis - abatacept (2nd line): British Society for Rheumatology (PDF 61 KB)

Rheumatoid arthritis - abatacept (2nd line): National Rheumatoid Arthritis Society (PDF 88 KB)

Rheumatoid arthritis - abatacept (2nd line): Primary Care Rheumatology Society (PDF 55 KB)

Rheumatoid arthritis - abatacept (2nd line): Royal College of Nursing (PDF 66 KB)

Rheumatoid arthritis - abatacept (2nd line): Royal College of Pathologists (PDF 56 KB)

Rheumatoid arthritis - abatacept (2nd line): Royal College of Physicians endorsing British Society for Rheumatology (PDF 79 KB)

Rheumatoid arthritis - abatacept (2nd line): manufacturer submission

Rheumatoid arthritis - abatacept (2nd line): BMS (PDF 1.55 MB)

Rheumatoid arthritis - abatacept (2nd line): clarification letter to manufacturer from NICE (PDF 53 KB)

Rheumatoid arthritis - abatacept (2nd line): clarification letter response (PDF 204 KB)

Rheumatoid arthritis - abatacept (2nd line): expert written personal statements

Rheumatoid arthritis - abatacept (2nd line): Bosworth

Rheumatoid arthritis - abatacept (2nd line): expert statement (PDF 25 KB)

Rheumatoid arthritis - abatacept (2nd line): submission (PDF 102 KB)

Rheumatoid arthritis - abatacept (2nd line): Burke (PDF 48 KB)

Rheumatoid arthritis - abatacept (2nd line): Kiely (PDF 24 KB)

Rheumatoid arthritis - abatacept (2nd line): Taylor (PDF 4.04 MB)

Rheumatoid arthritis - abatacept (2nd line): final scope (PDF 63 KB)

Rheumatoid arthritis - abatacept (2nd line): final matrix (PDF 55 KB)

Rheumatoid arthritis - abatacept (2nd line): comments on the draft scope (PDF 128 KB)

Rheumatoid arthritis - abatacept (2nd line): comments on the provisional matrix (PDF 37 KB)

Rheumatoid arthritis - abatacept (2nd line): appendix B draft scope for consultation (pre-referral) (PDF 69 KB)

Rheumatoid arthritis - abatacept (2nd line): appendix C provisional matrix (pre-referral) (PDF 62 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): evaluation report

Rheumatoid arthritis - tocilizumab (rapid review TA198): final scope (PDF 23 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): final matrix (PDF 58 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): manufacturer submission

Rheumatoid arthritis - tocilizumab (rapid review TA198): original submission for TA198, tocilizumb for the treatment of rheumatoid arthritis (PDF 2.14 MB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): Patient Access Scheme submission from Roche (PDF 337 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): Patient Access Scheme submission addendum from Roche (PDF 176 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): manufacturer comments on the appraisal consultation document from appraisal of TA198, tocilizumab for the treatment of rheumatoid arthritis

Rheumatoid arthritis - tocilizumab (rapid review TA198): ACD2 (PDF 320 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): ACD3

Rheumatoid arthritis - tocilizumab (rapid review TA198): ACD3 (PDF 168 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): letter accompanying updated model (PDF 37 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): review report by Decision Support Unit (DSU) (from the appraisal of TA198, tocilizumab for the treatment of rheumatoid arthritis and the rapid review of guidance TA198

Rheumatoid arthritis - tocilizumab (rapid review TA198): DSU report May 2010 (PDF 315 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): DSU report September 2011 (PDF 230 KB)

Rheumatoid arthritis - tocilizumab (rapid review TA198): matrix (PDF 23 KB)